



NICOLAS LECRENIER

PhD, Ing

GSK VACCINES, BELGIUM

Profile Summary

Master in Bio-engineering, and PhD in biology and biochemistry. Following my PhD, I joined Zeneca in the UK as a post-doc in genomics field.

I joined GSK Vaccines in 2001. In my current role, I am Global Medical Affairs Director for Shingrix. I have been leading Shingrix development for over 6 years, in early and late development stages, up to its approval in USA, Canada, EU and Japan in 2017-18.

I also led the development of GSK's quadrivalent influenza vaccines, and took part into HPV vaccine development, and universal influenza vaccine research. More recently I gained experience in the pneumococcal vaccine field as global medical affairs director.

+32-479 346 891

nlecrenier@gmail.com

GSK, Avenue Fleming 20, 1300
Wavre, Belgium

www.linkedin.com Nicolas Lecrenier

EDUCATION

BIO-ENGINEER 1986 – 1992
University of Louvain-la-Neuve - Belgium
Highest honours. Master thesis on **pertussis vaccine** improvement.
SmithKline Beecham, R&D, Belgium.

PhD molecular biology & biochemistry 1994 - 1999
University of Louvain-la-Neuve - Belgium
Study of mitochondrial DNA replication in yeast and cloning of human mitochondrial DNA polymerase.

WORK EXPERIENCE

GLOBAL MEDICAL AFFAIRS LEAD, SHINGRIX 2020- current
GSK Vaccines R&D - Belgium

GLOBAL MEDICAL AFFAIRS, SYNFLORIX 2018-2020
GSK Vaccines R&D - Belgium

VACCINE DEVELOPMENT LEADER, SHINGRIX 2016 - 2018
GSK Vaccines R&D - Belgium

VACCINE DEVELOPMENT LEADER FLU VACCINES 2010 - 2016
GSK Vaccine R&D - Belgium

CERVARIX VALUE STRATEGY 2009 - 2010
GSK Vaccines R&D - Belgium

EARLY DEVELOPMENT PROJECT LEADER 2005 - 2009
GSK Vaccines R&D - Belgium

**Zoster vaccine (Shingrix)
HPV Next Generation vaccine**

EXTRA-MURAL R&D BACTERIAL AND VIRAL 2001 - 2005
GSK Vaccines R&D - Belgium

POST-DOC TEAM LEADER 1999-2001
Syngenta (formerly Zeneca), Bracknell, UK

JUNIOR ASSOCIATE SCIENTIST 1992-1993
SmithKline Beecham, R&D, Belgium

MenB vaccine.

KEY PUBLICATIONS -

Lecrenier et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. *Expert Rev Vaccines*. 2018 Jul;17(7):619-634.

Nachbagauer R,, Lecrenier N A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. *NPJ Vaccines*. 2016;1

Spelbrink JN,, Lecrenier N. In vivo functional analysis of the human mitochondrial DNA polymerase POLG expressed in cultured human cells. *J Biol Chem*. 2000 Aug 11;275(32):24818-28

Lecrenier N, Foury F. New features of mitochondrial DNA replication system in yeast and man. *Gene*. 2000 Apr 4;246(1-2):37-48. Review. PubMed PMID: 10767525.

Rovio A,, Lecrenier N. Trinucleotide CAG repeat from the human mitochondrial DNA polymerase gene in healthy and diseased individuals. *Eur J Hum Genet*. 1999

Foury F,, Lecrenier N. The complete sequence of the mitochondrial genome of *Saccharomyces cerevisiae*. *FEBS Lett*. 1998;440(3):325-31.

Lecrenier N, Foury F, Goffeau A. Two-hybrid systematic screening of the yeast proteome. *Bioessays*. 1998 Jan;20(1):1-5.

Lecrenier N, Van Der Bruggen P, Foury F. Mitochondrial DNA polymerases from yeast to man: a new family of polymerases. *Gene*. 1997 Jan 31;185(1):147-52.

Lecrenier N, Foury F. Overexpression of the RNR1 gene rescues *Saccharomyces cerevisiae* mutants in the mitochondrial DNA polymerase-encoding MIP1 gene. *Mol Gen Genet*. 1995 Nov 1;249(1):1-7.